Genprex collaborators report positive preclinical data on the use of Reqorsa gene therapy at the 2025 AACR Annual Meeting

Genprex, Inc has announced that its research collaborators presented positive preclinical data for Reqorsa^® Gene Therapy (quaratusugene ozeplasmid), for the treatment of KRAS^G12C mutant non-small cell lung cancer (NSCLC). This data were presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, Illinois.

In the poster, entitled, 'Overcoming sotorasib acquired resistance in KRAS^G12C mutant NSCLC by TUSC2 gene therapy', researchers demonstrated that TUSC2 gene therapy (REQORSA) effectively overcomes sotorasib (LUMAKRAS^®) acquired resistance (AR) in KRAS^G12C mutant NSCLC mouse xenografts.

The data indicate that TUSC2 transfection significantly reduced colony formation and markedly increased apoptosis in two AR cell lines. Re-expression of TUSC2 in AR PDXOs significantly decreased the viability of organoids compared with the empty vector.

The H23AR tumors exhibited significantly lower sensitivity to sotorasib than their parental counterparts. However, treatment with REQORSA was highly effective in controlling tumor growth compared to treatment with sotorasib alone or the control groups. REQORSA alone also exhibited a strong antitumor effect on TC314AR PDXs. Sotorasib alone showed no significant antitumor activity in these models.

However, a synergistic antitumor effect was observed when TC314AR PDX tumors were treated with the combination of REQORSA and sotorasib. In conclusion, researchers demonstrated that REQORSA, alone or in combination with sotorasib, induced apoptosis, inhibited colony formation, and showed significant antitumor efficacy in KRAS^G12C mutant sotorasib-acquired resistant xenograft and PDX tumors.

"We are pleased to have this positive preclinical data presented before an audience of the world's leading cancer researchers, which provides further support for the therapeutic potential of REQORSA both alone and in combination with targeted therapies in NSCLC," said Ryan Confer, President and Chief Executive Officer at Genprex.

"We believe REQORSA could be a potential therapeutic treatment for Ras inhibitor resistant lung cancer either alone or in combination with Ras inhibitors, and these studies support the potential expansion of future clinical studies in our pipeline."

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>